Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Negative 57.9%

Neg 57.9% Neu 0% Pos 0%

Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.